Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.
about
Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulationIntra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophilaOritavancin: a new avenue for resistant Gram-positive bacteria.Oritavancin--an investigational glycopeptide antibiotic.Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts).Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthraxOritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenoIntracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinationsIntracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.Toward a new age of cellular pharmacokinetics in drug discovery.Novel avenues for Clostridium difficile infection drug discovery.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.Oritavancin: a review in acute bacterial skin and skin structure infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Oritavancin: a long-acting antibacterial lipoglycopeptide.Temporins A and B stimulate migration of HaCaT keratinocytes and kill intracellular Staphylococcus aureus.Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.Cellular pharmacokinetics and intracellular activity of gepotidacin against Staphylococcus aureus with different resistance phenotypes in models of cultured phagocytic cells.Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.A Cell-Penetrating Peptide Fused Phage Lysin Kills Intracellular MRSA in Keratinocytes and Treatment for Skin Infections of Mice.
P2860
Q33770082-F05D9060-F785-4591-9E5F-2069ADA29CA2Q33876454-173FC115-9A13-4F52-AE0D-0701EB3CD3E1Q34509728-4B739AA1-2F71-4526-9DE4-F304F90A52BCQ34618656-1ED8FD92-036D-496F-A186-24A83FD638B6Q36162339-27BFDFC6-4968-4780-950A-8CA764583FF7Q36426011-F495F6D5-E9A5-495B-8D2A-64DAB50A66B6Q36593797-45F8FF83-70E0-48F7-845A-3D0A80D2BD59Q36660619-5EC0FF12-8A87-491F-BD7E-2C7791BA812DQ36870766-93C2B378-583F-4D24-A15B-8512E1636F85Q37071199-6C3B15A0-2E3E-460C-B818-B6544590D332Q37144809-B1C81713-81F0-43C0-BD9E-60F7046AC189Q37144883-F9A8BB14-ADFB-4078-AB8E-5FDCE385E0B4Q37190843-AC97FDA6-A9D0-4177-A3AA-4B0D66A4B97FQ37851981-C87B5C3A-4292-4036-BC4B-414CFF0E290DQ38083297-6DFD841C-5BAE-49A8-93B2-A9A6ECDE004EQ38233471-215F389B-504F-4581-BD25-1D351934C8D1Q38364691-F58B256D-4D47-4A5B-813C-4DA59BAAF608Q38606618-9580D87F-E3B8-4B5F-A37D-169A67BCD977Q38646905-E3CDB660-D1D1-4FC1-9FC3-6843B5911991Q38830176-CE0EBA33-2D8F-4623-A3BF-B356DEC317B9Q38848646-98DCEB86-83C1-4A23-9A38-C673D9A26AC4Q39031976-8B32D1FF-367A-4198-AE64-444B1E6D6F09Q39373932-2092C27E-DAD8-4428-B562-6AFE5C8A1EB5Q39396626-0C5EAF8F-9D22-4CE1-BFAB-27CD4F29ACB6Q39715575-464195E9-9543-4970-B291-5801764A334EQ40201824-C66E6C7B-C8F4-4337-BEBE-96F9EC7A79ECQ49874631-C1A9A233-08F2-40E8-BB7A-F9EDFFA5AA95Q50053159-B87D99C8-D31D-4C94-A727-B2ED0F4D30DDQ51760113-76966729-280F-4243-B92C-FBB3468C26A0Q52601747-478C2E90-31F5-49DB-828A-D3B5AD9C44C1
P2860
Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cellular pharmacokinetics and ...... del of J774 mouse macrophages.
@ast
Cellular pharmacokinetics and ...... del of J774 mouse macrophages.
@en
type
label
Cellular pharmacokinetics and ...... del of J774 mouse macrophages.
@ast
Cellular pharmacokinetics and ...... del of J774 mouse macrophages.
@en
prefLabel
Cellular pharmacokinetics and ...... del of J774 mouse macrophages.
@ast
Cellular pharmacokinetics and ...... del of J774 mouse macrophages.
@en
P2093
P2860
P1476
Cellular pharmacokinetics and ...... odel of J774 mouse macrophages
@en
P2093
Cristina Seral
Donatienne Tyteca
Hugues Chanteux
Marie-Paule Mingeot-Leclercq
Stéphane Carryn
P2860
P304
P356
10.1128/AAC.48.8.2853-2860.2004
P407
P577
2004-08-01T00:00:00Z